FDA Approves First Blood Tests for Colorectal Cancer Screening: How They Work and What They Miss

Colorectal cancer is the second-leading cause of cancer-related deaths in the United States, yet it is also one of the most preventable. The paradox lies in the screening process. Despite clear guidelines recommending that average-risk adults begin screening at age 45, an estimated 60 million Americans remain completely unscreened.[4][5]

The primary barrier is the nature of the tests themselves. The gold standard, a colonoscopy, requires a day of fasting, a notoriously unpleasant bowel preparation regimen, and sedation. The primary alternative, an at-home stool test, requires patients to collect and mail their own fecal matter. For millions of people, the discomfort, time commitment, or "ick factor" is enough to delay screening indefinitely.[7][8]

To bridge this massive adherence gap, the U.S. Food and Drug Administration has ushered in a new era of diagnostic medicine by approving the first routine blood tests for colorectal cancer screening. Guardant Health’s Shield test became the first to cross the regulatory finish line, followed recently by Freenome’s SimpleScreen CRC.[3][5][6]

These approvals mean that primary care physicians can now screen for the second-deadliest cancer using a standard blood draw during an annual physical. However, while the convenience is revolutionary, the clinical data reveals significant trade-offs that patients and doctors must carefully navigate.[8]

The technology underpinning these tests is known as a "liquid biopsy." As cells in the body die and are replaced, they shed fragments of their genetic material into the bloodstream. This is known as cell-free DNA.[8]

When a tumor or an advanced polyp begins to grow in the colon, it also sheds DNA into the blood. This circulating tumor DNA carries specific epigenetic signatures—chemical modifications known as methylation patterns—that differentiate it from healthy DNA. The new FDA-approved tests use advanced sequencing and machine learning algorithms to hunt for these microscopic cancer signatures in a standard vial of blood.[1][2]

The clinical validation for these tests required massive, multi-year trials. The ECLIPSE trial, published in the New England Journal of Medicine, evaluated the Guardant Shield test in nearly 8,000 average-risk adults. The results demonstrated that the blood test correctly identified 83.1% of patients who had colorectal cancer.[1]

Similarly, the PREEMPT CRC trial, published in JAMA, evaluated Freenome’s test in over 27,000 participants. That study showed a 79.2% sensitivity for detecting colorectal cancer. Both tests also demonstrated high specificity, meaning they correctly returned a negative result in roughly 90% of people who did not have cancer, keeping false positives to a manageable level.[2]

While detecting roughly 80% of existing cancers with a simple blood draw is a major technological achievement, the tests struggle with the most crucial aspect of colorectal cancer screening: prevention. Colorectal cancer almost always begins as a benign growth called a polyp.[7]

During a colonoscopy, a gastroenterologist can visually identify these precancerous polyps and remove them on the spot, ensuring they never turn into cancer. Stool-based DNA tests, like Cologuard, are also reasonably effective at detecting these advanced precancerous lesions, catching about 43% of them.[7][8]

The blood tests, however, fall significantly short in this area. In the ECLIPSE trial, the Shield test detected only 13.2% of advanced precancerous lesions. The PREEMPT CRC trial showed a nearly identical 12.5% sensitivity for these early growths. Because polyps are small and have a limited blood supply, they simply do not shed enough DNA into the bloodstream to be reliably detected by current technology.[1][2]

This limitation has sparked a complex debate within the medical community. Gastroenterologists caution that widespread adoption of blood tests could shift the paradigm from cancer prevention to cancer detection. If a patient chooses a blood test over a colonoscopy, they may miss the opportunity to have a precancerous polyp removed, potentially allowing it to develop into a malignancy years later.[7]

Furthermore, a blood test is not a replacement for a colonoscopy; it is a triage tool. If a patient receives a positive result on a blood test, they must undergo a diagnostic colonoscopy to locate the tumor or polyp and determine the next steps. A positive blood test without a follow-up colonoscopy provides no clinical benefit.[3][4]

Despite these limitations, public health officials and the American Cancer Society have embraced the new technology with a pragmatic caveat. The updated guidelines position blood tests as a secondary option, explicitly recommending them for patients who refuse or are unable to complete a colonoscopy or a stool test.[4]

In the realm of public health, the most effective screening test is the one a patient will actually complete. By offering a frictionless option that requires no preparation and no handling of stool, these blood tests are poised to reach the millions of Americans who have historically avoided screening, undoubtedly saving lives by catching cancers that would have otherwise gone undetected until they were untreatable.[4][8]